In the relentless quest to find effective treatments for metastatic castration-resistant prostate cancer (mCRPC), a Phase I/II clinical trial of EPI-7386 in combination with enzalutamide has entered the spotlight, offering a glimpse of hope for patients grappling with this challenging condition.
October 23, 2023
Read moreThe 3-year update and final analysis of the Phase III MAGNITUDE study (NCT03748641) confirms that niraparib with abiraterone acetate plus prednisone (AAP) should be considered a new standard of care for the first-line treatment of patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC).
October 22, 2023
Read moreRecent findings showed that enzalutamide with or without leuprolide improved metastasis-free survival (MFS) while still preserving health-related quality of life among nonmetastatic hormone-sensitive prostate cancer (nmHSPC) patients with high-risk biochemical recurrence.
October 23, 2023
Read moreIn new research presented at the ESMO 2023 Congress, the ARAMIS trial has revealed the remarkable effects of darolutamide (DARO) in preserving health-related quality of life (HRQoL) deterioration-free survival (DetFS) based on prostate-specific antigen (PSA) decline (Abstract 1781P).
October 23, 2023
Read moreNew research from the ARASENS clinical trial has unveiled promising results regarding prostate-specific antigen (PSA) outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC). The study explored the effects of darolutamide (DARO) in combination with androgen-deprivation therapy (ADT) and docetaxel (DOC) on patients with both high-volume (HV) and low-volume (LV) mHSPC. The study was presented at the ESMO 2023 Congress, held in Madrid, Spain (Abstract 1784P).
October 22, 2023
Read moreIn the realm of metastatic castration-sensitive prostate cancer (mCSPC) treatment, the integration of novel therapies and precision medicine has been a game-changer. A recent study, presented by Chowdhury, et al, sheds light on the remarkable influence of rapid ultra-low prostate-specific antigen decline (UL PSA) in mCSPC patients undergoing treatment with apalutamide (APA) in combination with androgen deprivation therapy (ADT).
October 22, 2023
Read moreAdjuvant radiotherapy following radical prostatectomy demonstrated no meaningful benefit for patients with prostate cancer, according to final results from the Phase III RADICALS-RT study (NCT00541047) presented during the European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid, Spain (Abstract 1764O).
October 21, 2023
Read morePhase I findings demonstrated that treatment with xaluritamig was tolerable—with low-grade cytokine release syndrome—among heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC). This data, which was recently presented by William K. Kelly, DO, Chair of the Department of Medical Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, during the European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid, Spain, also showed encouraging preliminary efficacy in this patient population (Abstract 1765O).
October 21, 2023
Read moreA recent study found that patients with high-risk/locally advanced prostate cancer who had two risk factors or cN1 disease and underwent treatment with radiotherapy plus long-term ADT had a 5-year metastasis-free survival (MFS) rate of less than 80 percent and, therefore, were the individuals most likely to benefit from treatment intensification.
October 21, 2023
Read more